Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Photo: Misha Jordaan/Gallo Images via Getty Images
Johnson & Johnson has inked a deal with the African Union (AU) to supply up to 400 million doses of its coronavirus vaccine starting in the third quarter of the year, the drugmaker announced Monday.
Why it matters: Disparities in vaccine access remain a challenge for Africans, especially as the continent struggles to contain the coronavirus variant that originated in South Africa.
- South Africa has a vaccination rate of 0.3%, and most other African countries are on par with that number. The U.S. maintains a 34.6% vaccination rate, in contrast.
- The virus has infected 4.18 million people across Africa and killed almost 121,000, according to Reuters.
Details: J&J will deliver 220 million doses of its single-dose shot starting in the July-September quarter. The African Vaccine Acquisition Trust (AVAT) will be able to purchase an additional 180 million doses through 2022.
- Regulators in African countries must still authorize the vaccine, but the World Health Organization approved it for emergency use earlier this month.
- Data shows that the vaccine is 85% effective in preventing severe disease and protecting against different variants, including the variant from South Africa, 28 days after vaccination, the company said.
- Most of the supplies will be produced by Aspen Pharma in South Africa.
Our thought bubble, via Axios' Dave Lawler: The shots are to be manufactured mainly in South Africa, which would be a big development because right now there are virtually no shots being produced on the continent. And J&J’s vaccine could be particularly important to developing countries because it's relatively cheap and easy to ship and store, plus just a single shot.
What they're saying: "From the beginning of this pandemic, Johnson & Johnson has recognized that no one is safe until everyone is safe, and we have been committed to equitable, global access to new COVID-19 vaccines," Alex Gorsky, J&J chairman and CEO, said in a statement.
- "Our support for the COVAX Facility, combined with supplementary agreements with countries and regions, will help accelerate global progress toward ending the COVID-19 pandemic."